Advertisement

Search Results

Advertisement



Your search for Patricia A. Ganz, MD matches 37 pages

Showing 1 - 37


breast cancer

Patricia A. Ganz, MD, on Breast Cancer: Whole- vs Partial-Breast Irradiation

Patricia A. Ganz, MD, of NRG Oncology and Jonsson Comprehensive Cancer Center at UCLA, discusses the NRG/NSABP phase III findings, which showed that partial-breast irradiation was more convenient and resulted in less fatigue but slightly poorer cosmesis at 36 months in patients who did not receive...

survivorship

Patricia A. Ganz, MD, on Progress in Cancer Survivorship Care

Patricia A. Ganz, MD, of the University of California, Los Angeles, and this year’s recipient of the Ellen Stovall Award for Advancement of Cancer Survivorship Care, discusses her 30-year-long career researching and advocating for survivors and quality care.

breast cancer
symptom management

Patricia A. Ganz, MD: Aromatase Inhibitors Data Review

Patricia A. Ganz, MD, of the UCLA Jonsson Comprehensive Cancer Center, summarizes two studies on using duloxetine for aromatase inhibitor–associated musculoskeletal symptoms, and aromatase inhibitors’ effect on endothelial function and heart disease (Abstracts S5-06 and S5-07).

Expert Point of View: Patricia A. Ganz, MD & Gregory A. Masters, MD

“This is a tremendous advance. If we had a drug that could achieve these results we would rush to use it. This is also personalized medicine that alerts the health-care team when symptoms need addressing. And it is very important that using the app led to appropriate use of scans and tests, which...

Expert Point of View: Patricia Ganz, MD

Moderating a press conference where Dr. Chen presented his study findings, Patricia Ganz, MD, Director of Cancer Prevention and Control Research at the University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center, called this study “interesting and ­important.” She continued:...

ASCO Value in Cancer Care Task Force

The Value in Cancer Care Task Force was established in 2007 to educate oncologists about the importance of discussing costs associated with recommended treatments, empower patients to ask questions about the anticipated costs of their treatment options, identify the drivers of the rising costs of...

breast cancer

Study Finds No Association Between Anthracycline-Based Chemotherapy and Cognitive Decline in Women With Breast Cancer

A new study by University of California, Los Angeles (UCLA) researchers published by Van Dyk et al in JAMA Oncology found that commonly used chemotherapy drugs showed no association with cognitive decline following treatment in women with breast cancer. The report addresses recent concerns that the ...

breast cancer

Adjuvant Endocrine Therapy for Primary Breast Cancer Treatment Associated With Increased Symptom Burden Over 12 Months

Patients in the observational Mind-Body Study receiving adjuvant endocrine therapy for primary breast cancer treatment reported a greater symptom burden than did patients not receiving endocrine therapy over 12 months, as reported by Ganz et al in the Journal of Clinical Oncology. No differences in ...

issues in oncology

Patricia A. Ganz, MD, on Improving Quality and Value in Cancer Care

Patricia A. Ganz, MD, of the University of California at Los Angeles, the 2016 winner of the Joseph V. Simone Award, summarizes her “Lecture for Excellence in Quality and Safety in the Care of Patients With Cancer.”

Patricia A. Ganz, MD, Awarded Joseph V. Simone Award and Lecture for Excellence in Quality and Safety in the Care of Patients With Cancer

ASCO will honor Patricia A. Ganz, MD, an accomplished medical oncologist and renowned advocate for improving the quality of cancer care from prevention through survivorship, with its first annual Joseph V. Simone Award and Lecture for Excellence in Quality and Safety in the Care of Patients With...

breast cancer

Comparing Recurrence Risk With Anastrozole vs Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ

Two recently reported phase III trials compared adjuvant anastrozole vs tamoxifen in postmenopausal women with hormone receptor–positive ductal carcinoma in situ. As reported in The Lancet by Margolese et al,1 the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 trial, performed in...

breast cancer

Tamoxifen or Anastrozole for Ductal Carcinoma in Situ?

Ductal carcinoma in situ is a relatively benign form of breast cancer (stage 0), yet up to 10% of women with ductal carcinoma in situ will have a recurrence within 10 years. At present, there is no way to identify which women will recur, so standard treatment is lumpectomy plus radiation therapy....

supportive care

Patricia A. Ganz, MD, on Incorporating Psychosocial Services for Quality Cancer Care

Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses the Institute of Medicine report on patient-centered care, its relation to psychosocial services, and the role IPOS/APOS members can play.

survivorship

Patricia A. Ganz, MD, on Looking Beyond the Scans: What to Look For and How

Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses the limited sensitivity and specificity of surveillance testing for cancer recurrence and finding a better way to reassure patients about their continuing care.

SIDEBAR: The Survivorship Care Plan Document: A Flexible Tool

In the Journal of Oncology Practice,1 Erin E. Hahn, MPH, and Patricia A. Ganz, MD,  reported a qualitative study of cancer survivorship programs, based on in-depth interviews with teams from four institutions—an academic center, a community hospital, a primary care medical group, and a county...

survivorship

A Conversation with Patricia A. Ganz, MD

Researching the effects of cancer on patients’ quality of life and championing the development and implementation of survivorship care plans have been at the forefront of the 20-year-long career of Patricia A. Ganz, MD, Director of the Division of Prevention and Control Research at UCLA’s Jonsson...

prostate cancer

Data on Watchful Waiting for Low-risk Prostate Cancer May Swing Focus to Higher-risk Tumors and Quality of Life

Surgery did not increase survival rates compared to watchful waiting in men with clinically localized prostate cancer. Results were particularly strong for men with prostate-specific antigen (PSA) levels of 10 ng/dL and under, and those who have low-risk disease, according to data from the Prostate ...

prostate cancer

NIH Panel Endorses Active Surveillance in Low-risk Prostate Cancer

Active surveillance of localized prostate cancer is a viable management option that should be offered to low-risk patients in place of immediate treatment, said a panel of experts convened by the National Institutes of Health. A fairly new concept, active surveillance takes a more proactive...

Expert Point of View: Controlled Study Links ‘Chemobrain’ to Longitudinal Changes in Brain

Commenting on the study by Deprez et al, Patricia Ganz, MD, noted the importance of the finding for clinicians. “This study tells us that self-reported complaints mapped onto the neuropsychologic tasks; this has not been shown very often,” said Dr. Ganz, who is Director of the Division of Cancer...

survivorship

Controlled Study Links ‘Chemobrain’ to Longitudinal Changes in Brain

The phenomenon called “chemobrain”—impaired cognitive functioning following chemotherapy—correlates with longitudinal changes in the brain’s white matter, according a recent study in the Journal of Clinical Oncology.1 Structural changes in the white matter, measured by magnetic resonance diffusion...

Delivering Affordable Cancer Care: Is It Possible and What Will It Entail?

Many experts agree that at 18% of gross domestic product, health care (to paraphrase Shakespeare) is eating the country out of house and home. “The average cost of treating the most common cancers has increased, and as more expensive targeted therapies and other new technologies become the...

issues in oncology

Adolescents, Young Adults with Cancer Often Challenged By Unmet Needs Following Treatment 

About 70,000 adolescents and young adults (AYAs) between the ages of 15 and 39 are diagnosed with cancer each year, and in the past 30 years, there has been little or no improvement in survival in this population. In addition to the disease itself, they face many other challenges: reentry into...

health-care policy

IOM Report Illuminates U.S. Cancer Care Crisis and Offers Framework for Change

In September, the Institute of Medicine (IOM) of the National Academies issued its report, Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis,1 published more than a decade after its first study on the quality of cancer care in the United States. The authors of the...

survivorship

Benefits and Controversies in Survivorship Care Plans

Since the Institute of Medicine’s (IOM’s) 2005 report, From Cancer Patient to Cancer Survivor: Lost in Translation,1 survivorship plans have received growing attention. In short, a survivorship care plan is the record of a patient’s cancer history and recommendations for follow-up care. At ASCO’s...

survivorship

Addressing Patients’ Sexual Dysfunction Throughout Survivorship

Studies show that all cancers and related treatments have the potential to affect sexuality and sexual function. Surgery, chemotherapy, hormonal therapy, bone marrow transplantation, and radiation therapy can physically impact sexual health in myriad ways, including vaginal dryness, dyspareunia,...

survivorship
breast cancer

Mobile Patient-Centered App Tracks Breast Cancer Survivors’ Experiences

Patricia Ganz, MD, Director of Cancer Prevention and Control Research at the Jonsson Cancer Center of UCLA, and collaborators Apple and Sage Bionetworks, recently announced the launch of “Share the Journey: Mind, Body and Wellness after Breast Cancer,” a patient-centered mobile application (app)...

breast cancer
survivorship

‘Share the Journey’ Mobile App Aims to Understand the Different Experiences of Breast Cancer Survivors

In March 2015, Sage Bionetworks and Apple released “Share the Journey: Mind, Body, and Wellness After Breast Cancer,” a patient-centered iPhone app that tracks five common consequences of breast cancer treatment, including fatigue, cognitive function, sleep disturbances, mood changes, and a...

breast cancer

Patient-Reported Outcomes With Adjuvant Anastrozole vs Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ

As reported in The Lancet and at the recent San Antonio Breast Cancer Symposium, Ganz et al found differences in patient-reported outcomes with anastrozole vs tamoxifen in the phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 trial in postmenopausal women with hormone...

breast cancer

Patricia Ganz, MD, on Results from NSABP B-35: Patient-Reported Outcomes

Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses this clinical trial of anastrozole vs tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract S6-04).

breast cancer
issues in oncology

SABCS 2015: Patients With Ductal Carcinoma in Situ Receiving Anastrozole Reported Symptoms Different From Those in Patients Receiving Tamoxifen

Analysis of patient-reported outcomes, a secondary endpoint of the phase III NSABP B-35 clinical trial, in which anastrozole and tamoxifen were compared in postmenopausal women with ductal carcinoma in situ (DCIS) who underwent lumpectomy plus radiotherapy, found that there were no differences in...

breast cancer
gynecologic cancers
issues in oncology
issues in oncology
cost of care

Study Questions Cost-Effectiveness of Universal BRCA Screening

Women who are carriers of mutated BRCA genes are known to have a significantly higher risk for developing breast and ovarian cancers than those who do not have the mutations. A viewpoint published recently in JAMA Oncology by researchers at the University of California Los Angeles questioned...

breast cancer
survivorship
issues in oncology

New Study Reveals Effective Treatment Program for Breast Cancer Survivors With ‘Chemobrain’

In a new study, UCLA researchers have developed a cognitive rehabilitation program to address post-treatment cognitive changes, sometimes known as “chemobrain,” which can affect up to 35% of post-treatment breast cancer patients. Their findings were reported by Erocli et al in...

breast cancer

Language and Communication Cognitive Complaints Worsen After Initiation of Endocrine Therapy in Early-Stage Breast Cancer

Data suggest that cancer treatment puts patients at risk of cognitive impairment and that many patients exhibit impairment prior to treatment. In an observational cohort study reported in the Journal of Clinical Oncology, Ganz et al found that language and communication cognitive complaints were...

issues in oncology

ASCO 2014: Stopping Statins Is Safe and Can Improve Quality of Life for Patients With Cancer Near the End of Life

Stopping statin therapy is safe for patients with cancer who have a life expectancy of less than 1 year, according to a randomized study reported at the 2014 ASCO Annual Meeting in Chicago (Abstract LBA9514). Discontinuing statins did not shorten survival and provided a number of important...

breast cancer
survivorship

ASCO 2014: Goserelin Helps Preserve Fertility Among Women Receiving Chemotherapy for Hormone Receptor–Negative Breast Cancer

Adding goserelin (Zoladex) to standard chemotherapy may be an effective method of preserving fertility among women with early-stage hormone receptor–negative breast cancer, according to findings from a federally funded phase III clinical trial. In the S0230/POEMS study, reported at the 2014...

supportive care
issues in oncology

ASCO 2014: Starting Palliative Care Support for Family Caregivers at the Time of Cancer Diagnosis Improves Quality of Life

Introducing a palliative care support program for caregivers of patients with advanced cancer at or near the time patients are diagnosed provides greater benefits than delayed palliative care services, according to results of the ENABLE III study reported at the 2014 ASCO Annual Meeting in Chicago...

breast cancer
issues in oncology

ASCO 2014: Women With Breast Cancer and Bone Metastasis Can Safely Scale Back Frequency of Zoledronic Acid Dosing

Findings from a phase III randomized study suggest that women with breast cancer and bone metastasis who have received at least nine doses of zoledronic acid over the previous year can safely scale back dosing from every 4 weeks to every 12 weeks without compromising the effectiveness of the...

Advertisement

Advertisement



Advertisement